Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-11-12 00:00:00 ET · period of report 2025-11-07 · accession 0002001011-25-000098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-12 | 2025-11-07 | LGND | Gray Nancy Ryan | Dir | S - Sale+OE | $205.45 | -6,571 | 8,094 | -45% | -$1.35M |
| DM | 2025-11-12 | 2025-11-07 | LGND | Gray Nancy Ryan | Dir | M - OptEx | $69.58 | +6,571 | 11.1K | +145% | +$457.2K |
| DM | 2025-11-12 | 2025-11-07 | LGND | Gray Nancy Ryan | Dir | M - OptEx | $0.00 | -6,571 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-07 | S | D | 3,556 | $205.45 | 8,094 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-07 | S | D | 3,015 | $205.45 | 8,094 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-07 | M | A | 3,556 | $66.19 | 11,650 | D | — | — | |
| 4 | Common | Common Stock | 2025-11-07 | M | A | 3,015 | $73.57 | 11,109 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-07 | M | D | 3,015 | $0.00 | 0 | D | $73.57 · — to 2027-08-18 | 3,015 Common Stock | (F2) This Option was previously reported as a Grant of 3,452 shares, which vested in full on August 18, 2020, at an exercise price of $126.2600 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-07 | M | D | 3,556 | $0.00 | 0 | D | $66.19 · — to 2029-06-06 | 3,556 Common Stock | (F1) This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 06, 2020, at an exercise price of $113.5900 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |